Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

41. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn`s disease Full Text available with Trip Pro

Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn`s disease Comparative data on budesonide vs mesalamine for the treatment of mild-to-moderately active Crohn's disease (CD) are sparse. We assessed the efficacy and safety of each therapy in patients with mildly to moderately active CD.We performed a randomized, double-blind, double-dummy, 8-week, multicenter study in which 309 patients with mildly to moderately active CD received pH (...) -modified-release oral budesonide (9 mg/day once daily or 3 mg/day 3 times daily) or Eudragit-L-coated oral mesalamine (4.5 g/day).The primary efficacy variable, clinical remission (defined as Crohn's Disease Activity Index ≤150), at the final visit occurred in 69.5% (107 of 154) of patients given budesonide vs 62.1% (95 of 153) of patients given mesalamine (difference, 7.4%; 95% repeated confidence interval, -4.6% to 18.0%; P = .001 for noninferiority). Clinical remission rates did not differ

2011 EvidenceUpdates Controlled trial quality: predicted high

42. Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis

Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

43. Daily or intermittent budesonide in preschool children with recurrent wheezing. Full Text available with Trip Pro

Daily or intermittent budesonide in preschool children with recurrent wheezing. Daily inhaled glucocorticoids are recommended for young children at risk for asthma exacerbations, as indicated by a positive value on the modified asthma predictive index (API) and an exacerbation in the preceding year, but concern remains about daily adherence and effects on growth. We compared daily therapy with intermittent therapy.We studied 278 children between the ages of 12 and 53 months who had positive (...) values on the modified API, recurrent wheezing episodes, and at least one exacerbation in the previous year but a low degree of impairment. Children were randomly assigned to receive a budesonide inhalation suspension for 1 year as either an intermittent high-dose regimen (1 mg twice daily for 7 days, starting early during a predefined respiratory tract illness) or a daily low-dose regimen (0.5 mg nightly) with corresponding placebos. The primary outcome was the frequency of exacerbations requiring

2011 NEJM Controlled trial quality: predicted high

44. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis (Abstract)

Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus characterized by dense tissue eosinophilia; it is refractory to proton pump inhibitor therapy. EoE affects all age groups but most frequently individuals between 20 and 50 years of age. Topical corticosteroids are effective in pediatric patients with EoE, but no controlled studies of corticosteroids have been reported (...) in adult patients.We performed a randomized, double-blind, placebo-controlled trial to evaluate the effect of oral budesonide (1 mg twice daily for 15 days) in adolescent and adult patients with active EoE. Pretreatment and posttreatment disease activity was assessed clinically, endoscopically, and histologically. The primary end point was reduced mean numbers of eosinophils in the esophageal epithelium (number per high-power field [hpf] = esophageal eosinophil load). Esophageal biopsy and blood

2010 EvidenceUpdates Controlled trial quality: predicted high

45. Oral budesonide for induction of remission in ulcerative colitis. (Abstract)

Oral budesonide for induction of remission in ulcerative colitis. Corticosteroids remain one of the most popular medication choices for the induction of remission in ulcerative colitis and Crohn's disease. While corticosteroids may improve symptoms, they do not always result in mucosal healing and have significant adverse effects. Steroids which act topically, with less systemic side-effects may be more desirable. Oral budesonide, a topically acting corticosteroid with extensive first pass (...) hepatic metabolism, is effective in Crohn's disease and in enema formulation for left-sided ulcerative colitis. Data are limited regarding the role of oral budesonide in ulcerative colitis.To systematically review the safety and efficacy of oral budesonide for induction of remission in ulcerative colitis.Electronic searching of the MEDLINE and EMBASE databases was performed. Two authors independently reviewed all identified titles and abstracts. Full text articles of all potentially relevant studies

2010 Cochrane

46. Meta-analysis: Use of inhaled budesonide for 1 year does not increase risk of pneumonia in patients with chronic obstructive pulmonary disease

Meta-analysis: Use of inhaled budesonide for 1 year does not increase risk of pneumonia in patients with chronic obstructive pulmonary disease Use of inhaled budesonide for 1 year does not increase risk of pneumonia in patients with chronic obstructive pulmonary disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Use of inhaled budesonide for 1 year does not increase risk of pneumonia in patients with chronic obstructive

2010 Evidence-Based Medicine

47. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study (Abstract)

Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study Budesonide is effective in treating collagenous colitis, but no treatment is established for lymphocytic colitis. We performed a randomized, double-blind, placebo-controlled study to evaluate the effects of budesonide in patients with lymphocytic colitis.Forty-two patients (median age, 61 years) with lymphocytic colitis and chronic diarrhea were randomly assigned to groups that were given (...) oral doses of budesonide (9 mg/d) or placebo for 6 weeks. Nonresponders at week 6 were given open-label budesonide (9 mg/d) for 6 additional weeks. A complete colonoscopy and histologic and quality-of-life analyses were performed at baseline and at week 6. The primary end point was clinical remission at 6 weeks, with last observation carried forward (LOCF). All patients who left the study in clinical remission were followed for relapse.At week 6, 86% of patients given budesonide were in clinical

2009 EvidenceUpdates Controlled trial quality: predicted high

48. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol (Abstract)

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol Budesonide/formoterol maintenance and reliever therapy maintains asthma control and reduces exacerbation frequency compared with higher fixed-dose combination regimens. Its effects on eosinophilic airway inflammation and structure are unknown.We sought to compare the effects of budesonide/formoterol 200/6 microg twice daily plus as-needed with budesonide/formoterol 800/12 microg twice (...) daily on airway eosinophils and remodeling.This 52-week, parallel-group, randomized, double-blind study of 127 asthma patients who were symptomatic despite therapy compared (1) the change between induced sputum percent eosinophils at baseline and the geometric mean of 4 on-treatment values and (2) the change in endobronchial biopsy eosinophil counts pre- and post-treatment.Mean daily doses of budesonide/formoterol were 604/18 microg in the maintenance and reliever therapy group and 1,600/24 microg

2009 EvidenceUpdates Controlled trial quality: predicted high

49. Oral budesonide for maintenance of remission of Crohn`s disease: a pooled safety analysis Full Text available with Trip Pro

Oral budesonide for maintenance of remission of Crohn`s disease: a pooled safety analysis Budesonide exhibits similar efficacy to systemic glucocorticosteroids (GCSs) in Crohn's disease (CD), but with fewer adverse events (AEs). Aim To evaluate budesonide's safety profile in CD patients, in particular, incidences of clinically important AEs known to be associated with systemic GCSs.Five 1-year, double-blind, placebo-controlled trials evaluating budesonide for mild-to-moderate CD were pooled (...) for analysis.The highest incidence rates of AEs were gastrointestinal- and endocrine systems-related in both groups (budesonide 6 mg/day, n = 208; placebo, n = 209). Incidence rates were similar, except for higher incidence of endocrine disorders in budesonide versus placebo patients (P = 0.0042) caused by a higher overall occurrence of cutaneous GCS symptoms (P = 0.0036) in the budesonide group; differences in individual symptoms were nonsignificant. Percentage of patients with normal adrenal function

2009 EvidenceUpdates

50. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial (Abstract)

stools/day).Patients in clinical remission after 6 weeks' open-label therapy with oral budesonide (Entocort CIR capsules, 9 mg/day) received 24 weeks' double-blind maintenance therapy with budesonide 6 mg/day or placebo. Thereafter, patients entered the 24-week, blinded follow-up period.The proportion of patients in clinical remission (three or fewer stools/day) at the end of maintenance therapy.A total of 34 patients in remission at week 6 were randomly assigned to budesonide 6 mg/day (n = 17 (...) Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial To evaluate the efficacy and safety of long-term budesonide therapy for the maintenance of clinical remission in patients with collagenous colitis.Randomised, placebo-controlled study with a 24-week, blinded follow-up period without any treatment.Three gastroenterology clinics in Denmark.Forty-two patients with histologically confirmed collagenous colitis and diarrhoea (more than three

2009 EvidenceUpdates Controlled trial quality: predicted high

51. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

52. Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation

Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation Article Text Therapeutics Benefits

2009 Evidence-Based Medicine

53. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients (Abstract)

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients The adjustable-dose budesonide/formoterol dry powder inhaler (DPI) has demonstrated similar or greater asthma control with less inhaled corticosteroid compared with the fixed-dose budesonide/formoterol DPI.We sought to evaluate the efficacy, tolerability, and resource use of maintenance therapy with the adjustable (...) -dose budesonide/formoterol pressurized metered-dose inhaler versus the fixed-dose budesonide/formoterol pressurized metered-dose inhaler and the fixed-dose fluticasone propionate/salmeterol DPI.This was a randomized, open-label, multicenter study of patients (N = 1225) 12 years and older with moderate-to-severe persistent asthma. After 10 to 14 days of current therapy, patients were randomized 2:1 to fixed-dose budesonide/formoterol (160/4.5 microg x 2 inhalations [320/9 microg] twice daily

2008 EvidenceUpdates Controlled trial quality: uncertain

54. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study (Abstract)

Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study Budesonide is an inhaled steroid with a strong topical effect but with minimal systemic effects; it has been effectively delivered to animal lungs using surfactant as a vehicle. The purposes of this study were to determine whether early intratracheal instillation of budesonide using surfactant as a vehicle would improve pulmonary status, reduce mortality (...) , and reduce chronic lung disease morbidity.We conducted a prospective, randomized blind trial in 116 very low birth weight infants (< 1500 g) who had severe radiographic respiratory distress syndrome and required mechanical ventilation with fraction of inspired oxygen > or = 0.6 shortly after birth: 60 were in the treated group (intratracheal instillation of a mixture of 0.25 mg/kg of budesonide and 100.00 mg/kg of survanta, every 8 hours) and 56 were in the control group (100 mg/kg of survanta only

2008 EvidenceUpdates Controlled trial quality: uncertain

55. Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations

Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations Article Text Therapeutics Budesonide-formoterol for maintenance and as needed reliever

2008 Evidence-Based Medicine

56. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy

Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

57. Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma Full Text available with Trip Pro

Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma Article Text Therapeutics Maintenance plus

2006 Evidence-Based Medicine

58. Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations Full Text available with Trip Pro

Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations Article Text Treatment Maintenance and symptom relief with budesonide plus formoterol reduced severe

2006 Evidence-Based Nursing

59. Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol Drug Approval Package: Symbicort (budesonide/formoterol fumarate dihydrate) NDA #021929 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol Company: AstraZeneca Pharmaceuticals NDA: 021929 Approval Date: 7/21/2006 (PDF) (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF

2006 FDA - Drug Approval Package

60. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. (Abstract)

Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. The contributions of as-needed inhaled corticosteroids and long-acting beta2 agonists (LABA) to asthma control have not been fully established. We compared the efficacy and safety of three reliever strategies: a traditional short-acting beta2 agonist; a rapid-onset LABA (formoterol); and a combination of LABA and an inhaled corticosteroid (budesonide (...) -formoterol) in symptomatic patients receiving budesonide-formoterol maintenance therapy.We did a 12-month, double-blind, parallel-group study in 3394 patients (aged 12 years or older), in 289 centres in 20 countries, who were using inhaled corticosteroids at study entry and symptomatic on budesonide-formoterol (160 microg and 4.5 microg, respectively), one inhalation twice daily, during a 2-week run-in. After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one

2006 Lancet Controlled trial quality: predicted high